Sat 25 May 2013
|
Don't miss our
upcoming events
|
|
Brussels, 4-5 Oct. 2012
Preclinical/early clinical biomarker discovery
Vienna, 29 -30 Nov 2012
Present and future breast cancer management: bench to bedside and back
|
_______________________

Disclaimer
|
|
BDA Information
|
|
Click here to request information from BDA
|
Change text size © 2009 Biotherapy Development Association
|
|
Clinical services BDA researchers have extensive experience in cancer drug development, with particular strengths in early drug development with biological agents. Our clinical services include:
- Design of early clinical study protocols for solid tumour / haematological malignancies including the definition of surrogate markers and optimal biologically active dose to optimise the drug development programs.
- Advise on appropriate drug development strategies, clinical trial designs and latest trends in biotherapy development.
- Advise on the organisation of translational research accompanying early clinical studies
- Advise on strategies in combining biologicals with conventional anti-cancer drugs and therapies.
- Perform GCP-compliant clinical studies in our global network of centers.
- Carry out ongoing assessment of treatment response (both clinical and biological) to determine the optimal dose and schedule.
- Analyze and evaluate surrogate markers.
|